HomeCompareECGS vs ABBV

ECGS vs ABBV: Dividend Comparison 2026

ECGS yields 2000.00% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ECGS wins by $9939315158.43M in total portfolio value
10 years
ECGS
ECGS
● Live price
2000.00%
Share price
$0.10
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$9939315158.53M
Annual income
$9,049,252,674,478,578.00
Full ECGS calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — ECGS vs ABBV

📍 ECGS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodECGSABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ECGS + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ECGS pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ECGS
Annual income on $10K today (after 15% tax)
$170,000.00/yr
After 10yr DRIP, annual income (after tax)
$7,691,864,773,306,791.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ECGS beats the other by $7,691,864,773,285,735.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ECGS + ABBV for your $10,000?

ECGS: 50%ABBV: 50%
100% ABBV50/50100% ECGS
Portfolio after 10yr
$4969657579.32M
Annual income
$4,524,626,337,251,675.00/yr
Blended yield
91.05%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

ECGS
No analyst data
Altman Z
-45.2
Piotroski
2/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ECGS buys
0
ABBV buys
0
No recent congressional trades found for ECGS or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricECGSABBV
Forward yield2000.00%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$9939315158.53M$102.3K
Annual income after 10y$9,049,252,674,478,578.00$24,771.77
Total dividends collected$9876141646.27M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ECGS vs ABBV ($10,000, DRIP)

YearECGS PortfolioECGS Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$210,700$200,000.00$11,550$430.00+$199.2KECGS
2$4,163,767$3,938,317.76$13,472$627.96+$4.15MECGS
3$77,191,133$72,735,902.82$15,906$926.08+$77.18MECGS
4$1,342,813,676$1,260,219,163.76$19,071$1,382.55+$1342.79MECGS
5$21,925,333,121$20,488,522,486.99$23,302$2,095.81+$21925.31MECGS
6$336,109,296,351$312,649,189,912.21$29,150$3,237.93+$336109.27MECGS
7$4,838,913,266,619$4,479,276,319,522.88$37,536$5,121.41+$4838913.23MECGS
8$65,446,276,951,058$60,268,639,755,775.59$50,079$8,338.38+$65446276.90MECGS
9$831,834,097,245,644$761,806,580,908,011.90$69,753$14,065.80+$831834097.18MECGS
10$9,939,315,158,531,418$9,049,252,674,478,578.00$102,337$24,771.77+$9939315158.43MECGS

ECGS vs ABBV: Complete Analysis 2026

ECGSStock

Falcon Technologies, Inc. provides various design-build infrastructure services. The company offers telecommunications and data infrastructure services, which include communications infrastructure services to commercial, government, and other business enterprises. It also provides engineering services, program management, construction, installation and maintenance services, premise wiring services, tower and radio infrastructure services, and technology implementation and integration services, as well as a portfolio of infrastructure engineering and construction services. In addition, it offers design/build, installation, and maintenance services for electrical systems in factories, offices, healthcare facilities, government bases, and installations; and cell-phone relay towers, as well as sells electrical equipment, such as light fixtures, switchgear/panels, and fire alarm and control systems. Further, the company undertakes fire protection contracts in Northern California to provides layout and installation of various types of fire sprinkler systems, including wet and dry pipe, pre-action, in-rack, and fire pump systems in various commercial and industrial applications in new corporate headquarters, shopping centers, multi-tenant buildings, hospitals, nursing facilities, schools, and churches. Additionally, it offers emergency fire protection services with a fleet of approximately 25 service trucks. The company serves commercial builders/developers, government contractors, federal and state governments, education sector, and city/county. Falcon Technologies, Inc. is based in Rancho Cordova, California.

Full ECGS Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this ECGS vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ECGS vs SCHDECGS vs JEPIECGS vs OECGS vs KOECGS vs MAINECGS vs JNJECGS vs MRKECGS vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.